Compare Salesforce Inc (CRM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Salesforce Inc trades at $170 (market cap $137.23B), while State Street SPDR S&P Biotech ETF trades at $154.71. The key difference: Salesforce Inc pays a 1.05% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Salesforce Inc nearer its low. Which is the better fit depends on your goals.
| CRM | XBI | |
|---|---|---|
Market Cap | $137.23B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $270.25 | $164.28 |
52-Week Low | $150.12 | $85.16 |
Enterprise Value | $167.28B | — |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $171.22, up 4.84% over 24 hours, with a bullish technical signal despite mixed momentum indicators. The company demonstrates strong fundamentals, including a 77.64% gross margin and consistent earnings beats, with Q1 2026 EPS of $3.88 exceeding the $3.13 estimate. Revenue grew to $37.90B in 2025, and operating cash flow reached $13.09B. Recent news highlights AI-driven growth potential, though the stock faces sector-wide volatility.
Outlook remains positive with a consensus price target of $235.90, implying 38% upside, supported by 73 buy ratings. Risks include competitive pressures in SaaS and macroeconomic sensitivity. AI adoption and strong cash flow generation present key opportunities for long-term investors.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
